E protein silencing by the leukemogenic AML1-ETO fusion protein

Science
Jinsong ZhangRobert G Roeder

Abstract

The AML1-ETO fusion protein, generated by the t(8;21) chromosomal translocation, is causally involved in nearly 15% of acute myeloid leukemia (AML) cases. This study shows that AML1-ETO, as well as ETO, inhibits transcriptional activation by E proteins through stable interactions that preclude recruitment of p300/CREB-binding protein (CBP) coactivators. These interactions are mediated by a conserved ETO TAF4 homology domain and a 17-amino acid p300/CBP and ETO target motif within AD1 activation domains of E proteins. In t(8;21) leukemic cells, very stable interactions between AML1-ETO and E proteins underlie a t(8;21) translocation-specific silencing of E protein function through an aberrant cofactor exchange mechanism. These studies identify E proteins as AML1-ETO targets whose dysregulation may be important for t(8;21) leukemogenesis, as well as an E protein silencing mechanism that is distinct from that associated with differentiation-inhibitory proteins.

References

Feb 3, 1999·Proceedings of the National Academy of Sciences of the United States of America·I Engel, C Murre
Dec 28, 1999·Molecular and Cellular Biology·M E Massari, C Murre
Jul 21, 2001·Molecular and Cellular Biology·F CalabiG Pavloska
Nov 29, 2001·The Journal of Biological Chemistry·Maurice MarkusRobert Benezra
Feb 28, 2002·Annual Review of Immunology·Melanie W QuongCornelis Murre
May 29, 2002·Oncogene·Joseph M ScanduraStephen D Nimer
Jul 31, 2003·Trends in Cell Biology·Marianna B Ruzinova, Robert Benezra
Dec 20, 2003·The EMBO Journal·Isaac Engel, Cornelis Murre
May 25, 2004·Oncogene·Bruce A Hug, Mitchell A Lazar

❮ Previous
Next ❯

Citations

Oct 11, 2007·Mammalian Genome : Official Journal of the International Mammalian Genome Society·Keith C WeiserMonica J Justice
May 4, 2011·International Journal of Hematology·Susumu Goyama, James C Mulloy
Oct 22, 2005·Nature Immunology·Cornelis Murre
May 3, 2005·Nature Reviews. Cancer·Karen BlythJames C Neil
Jul 22, 2005·Nature Reviews. Cancer·Jonathan PerkRobert Benezra
Oct 24, 2009·Nature Reviews. Cancer·Adrian P Bracken, Kristian Helin
Feb 26, 2009·Nature Reviews. Immunology·Barbara L Kee
Feb 10, 2009·Proceedings of the National Academy of Sciences of the United States of America·Colin KwokChi Wai Eric So
Sep 26, 2013·Nucleic Acids Research·Chien-Hung GowJinsong Zhang
Jul 23, 2013·Genes & Development·Wei-Yi ChenRobert G Roeder
Apr 5, 2013·Genome Research·Eugenia G Giannopoulou, Olivier Elemento
Sep 6, 2012·Molecular and Cellular Biology·Ioanna ZarifiChristos Delidakis
May 4, 2011·Molecular and Cellular Biology·Aubrey HuntScott W Hiebert
Aug 18, 2006·Molecular and Cellular Biology·Richard BaylyDavid P LeBrun
Feb 23, 2012·Molecular and Cellular Biology·Robert TeachenorCornelis Murre
Apr 2, 2009·Molekuliarnaia biologiia·M V FalaleevaA B Chetverin
Jan 31, 2009·Blood·Liya RoudaiaNancy A Speck
Oct 14, 2009·Blood·Erin A KimbrelAndrew L Kung
May 1, 2010·Blood·Christian WichmannManuel Grez
Aug 18, 2005·International Journal of Hematology·Tetsuya YamagataKinuko Mitani
Dec 29, 2011·Frontiers in Bioscience (Landmark Edition)·Kentson Lam, Dong-Er Zhang
Dec 23, 2010·Future Oncology·Etienne De BraekeleerMarc De Braekeleer
May 12, 2012·Clinical & Developmental Immunology·Marsela Braunstein, Michele K Anderson
Dec 1, 2004·Proceedings of the National Academy of Sciences of the United States of America·Ming YanDong-Er Zhang
Mar 7, 2014·Trends in Molecular Medicine·Marc P ForrestDerek J Blake

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.